MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jdin.2025.09.022

Медицинская библиотека · JAAD international · 2025

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP).

Duffin Kristina Callis, Griffiths Christopher E M, Hoffmann Matthias, Blauvelt Andrew, Balagula Yevgeniy, Napoli Andrew, Becker Brandon, Jou Ying-Ming, Dyme Rachel, Hala Virginia, Pinter Andreas, Thaçi Diamant, Gold Linda Stein, Lebwohl Mark

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

OBJECTIVE

The 52-week, phase 3b/4 PSORIATYK SCALP (NCT05478499) trial evaluated deucravacitinib efficacy and safety in scalp psoriasis, including patients with more limited overall psoriasis. Here, we report week 16 results.

METHODS

Adults with moderate to severe scalp psoriasis and body surface area involvement ≥ 3% were randomized 1:2 to placebo (n = 51) or deucravacitinib 6 mg once daily (n = 103) through week 16. The primary efficacy endpoint was scalp-specific Physician Global Assessment score of 0/1; key secondary endpoints were Psoriasis Scalp Severity Index 90, scalp-specific numeric rating scale itch score, and static Physician Global Assessment (sPGA) 0/1.

RESULTS

In the overall population, scalp-specific Physician Global Assessment score of 0/1 (48.5% vs 13.7%; P < .0001), Psoriasis Scalp Severity Index 90 (38.8% vs 2.0%; P < .0001), and mean change from baseline in scalp-specific numeric rating scale itch (-3.2 vs -0.7; P < .0001) were superior with deucravacitinib versus placebo. In the sPGA ≥ 3 subpopulation, sPGA 0/1 was superior with deucravacitinib (51.0% vs 4.3%; P < .0001). Adverse events were comparable between groups.

LIMITATIONS: 16-week analysis.

CONCLUSION

Deucravacitinib was efficacious and well tolerated in patients with moderate to severe scalp psoriasis.

Для цитирования: Duffin Kristina Callis, Griffiths Christopher E M, Hoffmann Matthias, Blauvelt Andrew, Balagula Yevgeniy, Napoli Andrew, Becker Brandon, Jou Ying-Ming, Dyme Rachel, Hala Virginia, Pinter Andreas, Thaçi Diamant, Gold Linda Stein, Lebwohl Mark. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP).. JAAD international. 2025. DOI: 10.1016/j.jdin.2025.09.022.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.